• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

Introduction to 5-(6-amino-9H-purin-9-yl)pentanoic acid (CAS No. 90973-36-7)

5-(6-amino-9H-purin-9-yl)pentanoic acid, identified by the Chemical Abstracts Service registry number 90973-36-7, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and biochemical research. This compound belongs to the class of purine derivatives, which are well-documented for their diverse biological activities and potential therapeutic applications. The structural configuration of 5-(6-amino-9H-purin-9-yl)pentanoic acid incorporates a pentanoic acid moiety linked to a substituted purine ring, making it a versatile scaffold for further chemical modifications and biological investigations.

The purine core of this molecule is particularly noteworthy, as purines are fundamental components of nucleic acids and play critical roles in cellular metabolism and signaling pathways. The presence of an amino group at the 6-position of the purine ring enhances its reactivity, allowing for conjugation with other bioactive molecules or incorporation into more complex synthetic pathways. This structural feature makes 5-(6-amino-9H-purin-9-yl)pentanoic acid a valuable intermediate in the synthesis of novel pharmacological agents targeting various disease mechanisms.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors that modulate purine-based signaling pathways. These pathways are implicated in a wide range of physiological processes, including cell proliferation, inflammation, and neurotransmission. The pentanoic acid side chain in 5-(6-amino-9H-purin-9-yl)pentanoic acid provides a hydrophobic anchor that can be exploited to optimize drug-like properties such as solubility, bioavailability, and target specificity. Such structural attributes are crucial for designing compounds with improved pharmacokinetic profiles.

One of the most compelling aspects of 5-(6-amino-9H-purin-9-yl)pentanoic acid is its potential application in the development of antiviral and anticancer agents. Purine analogs have long been explored as inhibitors of viral enzymes and as agents that disrupt tumor cell proliferation. For instance, recent studies have demonstrated the efficacy of purine derivatives in inhibiting enzymes such as adenosine kinase and hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which are essential for nucleotide biosynthesis in rapidly dividing cells. The amino group at the 6-position of the purine ring in 5-(6-amino-9H-purin-9-yl)pentanoic acid offers a site for further functionalization, enabling the design of more potent and selective inhibitors.

The synthesis of 5-(6-amino-9H-purin-9-yl)pentanoic acid involves multi-step organic transformations that require precise control over reaction conditions to ensure high yield and purity. Key synthetic strategies include condensation reactions between appropriately substituted purines and pentanoic acid derivatives, followed by purification techniques such as column chromatography or recrystallization. Advances in synthetic methodologies have made it possible to produce this compound on a scalable basis, facilitating its use in both academic research and industrial applications.

From a biochemical perspective, 5-(6-amino-9H-purin-9-yl)pentanoic acid serves as a useful tool for investigating enzyme-substrate interactions and for developing enzyme inhibitors. Its ability to mimic natural purine derivatives allows researchers to probe the mechanisms of enzymes involved in nucleotide metabolism. Additionally, its structural flexibility makes it an attractive candidate for structure-based drug design, where computational modeling is used to predict how small molecules will interact with biological targets.

The pharmaceutical industry has shown particular interest in 5-(6-amino-9H-purin-9-yl)pentanoic acid due to its potential as a lead compound for drug discovery programs. By systematically modifying its structure, researchers can generate libraries of derivatives with tailored biological activities. For example, introducing additional functional groups or altering the length of the pentanoic acid side chain can fine-tune properties such as binding affinity and metabolic stability. Such modifications are critical for optimizing drug candidates for clinical development.

In conclusion, 5-(6-amino-9H-purin-9-yl)pentanoic acid (CAS No. 90973-36-7) is a multifaceted compound with significant potential in pharmaceutical research. Its unique structural features—combining a purine core with an amino-substituted pentanoic acid moiety—make it a valuable scaffold for developing novel therapeutic agents. As our understanding of biological pathways continues to evolve, compounds like 5-(6-amino-9H-purin-9-y]pentanoic acid will undoubtedly play an increasingly important role in addressing complex diseases through innovative drug design strategies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)